精神疾病精神药理学的新见解。
New Insights in Psychiatric Disorder Psychopharmacology.
作者信息
Shalbafan Mohammadreza, Orsolini Laura
机构信息
Mental Health Research Center, Psychosocial Health Research Institute (PHRI), Department of Psychiatry, School of Medicine, Iran University of Medical Sciences, Tehran 14496-14535, Iran.
Brain and Cognition Clinic, Institute for Cognitive Sciences Studies, Tehran 14496-14535, Iran.
出版信息
Brain Sci. 2025 Mar 19;15(3):319. doi: 10.3390/brainsci15030319.
Abstract
Psychopharmacological interventions are the treatment cornerstone of most psychiatric disorders such as depression, schizophrenia, obsessive-compulsive disorder, and bipolar disorders, with a huge number of studies including clinical trials and review articles deepening knowledge in the field in recent decades [...].
摘要
心理药理学干预是大多数精神疾病（如抑郁症、精神分裂症、强迫症和双相情感障碍）的治疗基石，近几十年来，大量研究（包括临床试验和综述文章）加深了该领域的知识……
相似文献
1
New Insights in Psychiatric Disorder Psychopharmacology.精神疾病精神药理学的新见解。
Brain Sci. 2025 Mar 19;15(3):319. doi: 10.3390/brainsci15030319.
2
Comparative mortality risk in adult patients with schizophrenia, depression, bipolar disorder, anxiety disorders, and attention-deficit/hyperactivity disorder participating in psychopharmacology clinical trials.精神药理学临床试验中成年精神分裂症、抑郁症、双相情感障碍、焦虑症和注意缺陷多动障碍患者的比较死亡率风险。
JAMA Psychiatry. 2013 Oct;70(10):1091-9. doi: 10.1001/jamapsychiatry.2013.149.
3
The psychopharmacological management of RLS in psychiatric conditions: a review of the literature.精神疾病中不宁腿综合征的精神药理学治疗：文献回顾。
J Am Psychiatr Nurses Assoc. 2012 Jul-Aug;18(4):214-25. doi: 10.1177/1078390312442569. Epub 2012 Apr 22.
4
A selected review of recent biological psychiatric research in China (translated version).中国近期生物精神病学研究精选综述（翻译版）
East Asian Arch Psychiatry. 2010 Mar;20(1):44-50.
5
Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis.成人强迫症管理的药理学和心理治疗干预措施：一项系统评价和网状荟萃分析
Lancet Psychiatry. 2016 Aug;3(8):730-739. doi: 10.1016/S2215-0366(16)30069-4. Epub 2016 Jun 16.
6
The Psychopharmacology of Obsessive-Compulsive Disorder: A Preclinical Roadmap.强迫症的精神药理学：临床前路线图。
Pharmacol Rev. 2020 Jan;72(1):80-151. doi: 10.1124/pr.119.017772.
7
Somatic treatments excluding psychopharmacology in obsessive- compulsive disorder: a review.强迫症中不包括精神药理学的躯体治疗：一项综述。
Rev Recent Clin Trials. 2013 Jun;8(2):119-23. doi: 10.2174/15748871113086660049.
8
N-acetylcysteine as a new prominent approach for treating psychiatric disorders.N-乙酰半胱氨酸作为治疗精神障碍的一种新的突出方法。
Br J Pharmacol. 2021 Jul;178(13):2569-2594. doi: 10.1111/bph.15456. Epub 2021 May 5.
9
An update on publicly funded multisite trials in pediatric psychopharmacology.儿科精神药理学领域公共资助多中心试验的最新情况。
Child Adolesc Psychiatr Clin N Am. 2006 Jan;15(1):1-12. doi: 10.1016/j.chc.2005.08.010.
10
Comparative neuropsychiatry: white matter abnormalities in children and adolescents with schizophrenia, bipolar affective disorder, and obsessive-compulsive disorder.比较神经精神病学：精神分裂症、双相情感障碍和强迫症儿童和青少年的脑白质异常。
Eur Psychiatry. 2015 Feb;30(2):205-13. doi: 10.1016/j.eurpsy.2014.10.003. Epub 2014 Dec 12.
本文引用的文献
1
Effectiveness and safety of aripiprazole oral solution in the acute treatment of schizophrenia in Chinese patients.阿立哌唑口服溶液在中国患者中急性治疗精神分裂症的有效性和安全性。
BMC Psychiatry. 2024 Dec 30;24(1):959. doi: 10.1186/s12888-024-06455-y.
2
The effects of L-theanine supplementation on the outcomes of patients with mental disorders: a systematic review.补充L-茶氨酸对精神障碍患者预后的影响：一项系统评价。
BMC Psychiatry. 2024 Dec 4;24(1):886. doi: 10.1186/s12888-024-06285-y.
3
Short-term safety and tolerability profile of 5-methoxy-N,N-dimethyltryptamine in human subjects: a systematic review of clinical trials.5-甲氧基-N,N-二甲基色胺在人体受试者中的短期安全性和耐受性概况：临床试验的系统评价
Front Psychiatry. 2024 Sep 19;15:1477996. doi: 10.3389/fpsyt.2024.1477996. eCollection 2024.
4
A randomized controlled pilot study of daily intravenous ketamine over three days for treatment-resistant depression.一项为期三天的每日静脉注射氯胺酮治疗难治性抑郁症的随机对照初步研究。
BMC Psychiatry. 2024 Jul 18;24(1):512. doi: 10.1186/s12888-024-05951-5.
5
Effect of duloxetine on changes in serum proinflammatory cytokine levels in patients with major depressive disorder.度洛西汀对抑郁症患者血清促炎细胞因子水平变化的影响。
BMC Psychiatry. 2024 Jun 14;24(1):449. doi: 10.1186/s12888-024-05910-0.
6
Efficacy of empagliflozin as adjunctive therapy to citalopram in major depressive disorder: a randomized double-blind, placebo-controlled clinical trial.恩格列净作为西酞普兰辅助治疗重性抑郁障碍的疗效：一项随机、双盲、安慰剂对照临床试验。
BMC Psychiatry. 2024 Feb 26;24(1):163. doi: 10.1186/s12888-024-05627-0.
7
Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant.用于治疗失眠的双重食欲素受体拮抗剂：对苏沃雷生和伦博雷生的随机、双盲、安慰剂对照试验的系统评价和荟萃分析。
Front Psychiatry. 2022 Dec 12;13:1070522. doi: 10.3389/fpsyt.2022.1070522. eCollection 2022.
8
Fluvoxamine combination therapy with tropisetron for obsessive-compulsive disorder patients: A placebo-controlled, randomized clinical trial.氟伏沙明联合曲唑酮治疗强迫症患者的随机双盲安慰剂对照临床试验。
J Psychopharmacol. 2019 Nov;33(11):1407-1414. doi: 10.1177/0269881119878177. Epub 2019 Oct 1.
Zotero 插件